Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Metabolism of GLPG1205 in Healthy Male Subjects
NCT04704739Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GLPG1205 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Galapagos NV. Primary endpoints: Absolute oral bioavailability (F) at Day 22 and Recovery of total radioactivity in urine and feces at Day 22. Started Jan 2021; status: completed.
02
Drugs
GLPG1205
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04704739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704739.